_quizartinib-advances-overall-survival-in-acute-myeloid-leukaemia-patients.jpg "Quizartinib advances overall survival in acute myeloid leukaemia patients from flt3 itd mutation positive Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 14 sec
✓ Published: 11-Jun-2022
✓ Published: 11-Jun-2022
Description:
Dr Harry Erba speaks to ecancer at the EHA 2022 meeting about quizartinib improving the overall survival in adult patients with FLT3-ITD+ acutenmyeloid leukaemia.nn Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults, and approximately 25% of all newly diagnosed cases carry the FLT3-internal tandem duplication (ITD) gene mutation.nnThe results showed that the addition of quizartinib significantly improved overall survival compared with standard induction and consolidation
Dr Harry Erba speaks to ecancer at the EHA 2022 meeting about quizartinib improving the overall survival in adult patients with FLT3-ITD+ acutenmyeloid leukaemia.nn Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults, and approximately 25% of all newly diagnosed cases carry the FLT3-internal tandem duplication (ITD) gene mutation.nnThe results showed that the addition of quizartinib significantly improved overall survival compared with standard induction and consolidation
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_best-treatment-strategy-for-flt3-itd-aml.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_quizartinib-for-flt3-itd-positive-aml-after-second-line-chemo-or-stem-cell-transplant.webp "Research suggests that a new targeted therapy, quizartinib, may be a safe and effective option to treat a subset of patients with treatment-resistant acute myeloid leukaemia (AML), whose leukaemia has the FLT3-ITD mutation.nnQuizartinib is the first and only single-agent drug that has produced a clinical benefit in AML patients with this deadly mutation who have failed previous therapy.nnThe number of patients bridged to a stem cell transplant was very significant. Dr Levis and his colleagues pl")
⏲ 3 min 26 sec ✓ 16-Jan-2018
_significance-of-flt3-mutations-in-aml.webp "OncLiveTV")
_aml17-trial-update-flt3-itd-mutation-and-daunorubicin-dosage.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_what-is-flt3-mutated-acute-myeloid-leukemia.webp "Patient Empowerment Network")
_dr-rllig-on-flt3-itd-npm1-mutation-status-for-patients-with-aml.webp "Targeted Oncology")
_sf3b1-as-therapeutic-target-in-flt3-itd-positive-aml.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_prognostic-impact-of-flt3-itd-in-older-patients-with-aml.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_best-treatment-strategy-for-flt3-itd-aml.jpg)
_quizartinib-for-flt3-itd-positive-aml-after-second-line-chemo-or-stem-cell-transplant.jpg)
_significance-of-flt3-mutations-in-aml.jpg)
_aml17-trial-update-flt3-itd-mutation-and-daunorubicin-dosage.jpg)
_what-is-flt3-mutated-acute-myeloid-leukemia.jpg)
_dr-rllig-on-flt3-itd-npm1-mutation-status-for-patients-with-aml.jpg)
_sf3b1-as-therapeutic-target-in-flt3-itd-positive-aml.jpg)
_prognostic-impact-of-flt3-itd-in-older-patients-with-aml.jpg)
![[+]](/images/menu.gif){kind=small}